Baltimore, United States
Kubanda Cryotherapy is pioneering a breakthrough in veterinary medicine by offering the first minimally invasive, non-surgical treatment for masses in pets. Utilizing an innovative approach that evolves the well-established technique of cryotherapy from human healthcare, their CryoNeedle system provides an effective and quicker alternative to traditional surgical methods, prioritizing pet recovery and comfort.
Founded in 2018 and headquartered in the United States, Kubanda Cryotherapy has completed rigorous research and trials, including at the prestigious Johns Hopkins Hospital, over six years. This evidence-based approach ensures reliability as they enter the market to serve pet clinics worldwide.
In a recent financial milestone, the company secured a $150.00K Pre Seed Round investment from Boot64 Ventures on 25 September 2023. This investment underscores growing confidence in Kubanda Cryotherapy's potential to transform veterinary cancer care, aligning human-grade innovation with pet health.
